Silimarina
Silimarina (Silybum Marianum)- foto Familia: Asteraceae/Compositaea
| Silimarina (Silybum Marianum) extract standardizat Silimarina 80%
din: Farmacia Naturala |
 |
| Silimarina cu puritate si concentratie de: Silimarina 80% |
 |
3. Silimarina
un antioxidant flavonoid, structura, functie si uz clinic
4. Efect
stimulator Silimarina, Silibinina si Silicristina la celulele de rinichi
5. Silimarina
impreuna cu izomerul sau Silibina cu efect
la pacienti cu colecistectomie
6. Silimarina
inhiba peroxidarea lipidica
7. Silimarina
antioxidant efectiv in tratamentul de hiperinsulinemie la pacienti
diabetici
8. Consumul
de Silimarina in tratarea bolilor cronice hepatice
9. Silimarina
in prevenirea de ciroza hepatica
10. Silimarina indicat in infectii de hepatite virale acute, studiu
randomizat,
dublu-orb, placebo controlat
11. Silimarina indicat in hepatite si hepatite cronice, studiu randomizat,
dublu-orb, placebo
controlat
12. Silimarina un antioxidant, flavonoid si lignani reduce valorile
ale lipoproteinelor cu densitate joasa (colesterolul-LDL) la persoane cu
hipercolesterolemie
si hiperlipoproteinemie
13. Silimarina indicat in hiperinsulinemie la pacienti cu ciroza
hepatica si diabet
zaharat
| Silimarina indicat la diabet zaharat |
 |
14. Silimarina indicat in ciroza hepatica, studiu randomizat, dublu-orb,
placebo
controlat
15. Silimarina indicat in ciroza hepatica si hepatita alcolica,
studiu randomizat, dublu-orb, placebo
controlat
16. Silimarina
reduce progresia de fibroza hepatica
17. Silmarina
si Silibinina izomer al silimarinei inhiba invazia cancerului de plamin,
reduce
enzima urokinaza si
metaloproteinaza matricial-2
18. Silimarina inhiba activitatea de telomeraza si antigenul specific
prostatic, silibinina
previne cancerul de prostata
19. Silibina izomer al silimarinei cu efect antiproliferativ in maligne
ginecologice si cancer
mamar
20. Silimarina un natural antioxidant, flavonoid polifenolic inhiba
carcinogeneza
in colon
21. Silimarina ca
flavonoid cu efect in intoxicatia de medicamente, studiu randomizat, dublu-orb,
placebo
controlat
22. Silimarina si Vitamina B complex in tratamentul de boli cronice
hepatice, sistematic reviu
cu meta analiza
23. Silimarina extract
cu efect imunostimulator
24. Silimarina in
tratamentul de Alzheimer
25. Silimarina cu
cu efect la pacienti cu colestaza
26. Silimarina previne
iradierea de raze ultraviolete UV-A
27. Acid
alfa lipoic, Silimarina si Seleniu ca antioxidanti in tratamentul de hepatita
C
28. Studiu
comparativ intre Silimarina si complex de Silibina si Fosfatildilcolina in
hepatita cronica activa, studiu randomizat, dublu-orb, placebo
controlat
Hepato Formula un complex de Silimarina
si Fosfatidilcolina 35 %
29. Interferon-Alpha si
Ribavirina la pacienti cu hepatita C cronica, care nu raspunde la tratamente
anterioare, studiu randomizat dublu orb placebo controlat cu studiu multi
centru
30. Stabilizarea functiei hepatice cu Interferon-Alpha si Ribavirina la terapia antivirala de ciroza progresiva
Recomandare la hepatita C:
- Interferon-Alpha 3 milioane U.I subcutan de 3 ori pe saptamina timp
de 6 luni de zile
- Ribavirina 3 x 400 mg pe zi (1000 - 1200 mg pe zi) 6 luni de zile
impartite iar ca tratament adjuvant:
- EGCG 50% 300 - 900 mg pe zi
- Garlic 3000 - 4000 mg pe zi
- Silimarina 200 mg - 500 mg pe zi
- Fosfatidilcolina 35% 400mg - 800 mg pe zi
- N-Acetilcisteina 500 mg - 1500 mg pe zi
- Acid Alfa Lipoic 250 mg - 500 mg pe zi
- Struguri Rosii OPC 95% 100 mg - 300 mg pe zi
- Melatonina 500 mcg - 6 mg inainte de culcare
- VITAMINA E 400 UI - 800 UI pe zi
| Bibliografie-Referinte: |
 |
1. Mira ML, Azevedo MS, Manso C. The
neutralization of hydroxyl radical by silibin, sorbinil and bendazac. Free
Radic Res Commun 1987. 4:125-9.
- Valenzuela A, Guerra R, Videla LA.
Antioxidant
properties of the flavonoids silybin and (+)-cyanidanol-3: Comparison
with butylated hydroxyanisole and butylated hydroxytoluene. Planta Med 1986.
6:438-40.
-
Dehmlow C, Murawski
N, de Groot H. Scavenging
of reactive oxygen species and inhibition of arachidonic acid metabolism
by silibinin in human cells.
Life Sci 1996. 58:1591-600.
- Johnson VJ, He Q, Osuchowski MF, Sharma RP. Physiological responses of a
natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin
inhibits
T-lymphocyte function at low doses but stimulates inflammatory processes
at high doses. Planta Medica. 2003;69(1):44-49.
2. Tenney L. Milk thistle: A remarkable
flavonoid antioxidant and liver protectant. Pleasant Grove (UT): Woodlands
Publications; 1995.
- Lapis, K., A. Jeney, et al. (1986). "Experimental studies on the effect
of hepatoprotective compounds." Tokai J Exp Clin Med 11(Suppl): 135-45.
- Feher J, Lengyel G, Blazovics A. Oxidative
stress in the liver and biliary
tract diseases. Scand J Gastroenterol Suppl 1998. 228:38-46.
3. Miller AL. Antioxidant flavonoids:
Structure, function and clinical usage.
Altern Med Rev 1996. 1:103-11.
4. Sonnenbichler J et al, Stimulatory effects
of silibinin and silicristin from the milk thistle
Silybum marianum on kidney cells, J Pharmacol Exp Ther 1999;290(3):1375-83
5. Schandalik R, Gatti G, Perucca E. Pharmacokinetics
of silybin in bile following administration of silipide and silymarin in cholecystectomy
patients. Arzneimittelforschung 1992. 42:964-8.
6. Bindoli A, Cavallini L, Siliprandi
N. Inhibitory
action of silymarin of lipid peroxide formation in rat liver mitochondria
and microsomes. Biochem Pharmacol 1977. 26:2405-9.
7. Velussi M, Cernigoi AM, De Monte
A, et al. Long-term
(12 months) treatment with an anti-oxidant drug (silymarin) is effective
on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in
cirrhotic diabetic patients. J Hepatol 1997. 26:871-9.
8. Tanasescu, C., S. Petrea,
et al. (1988). "Use of the Romanian product Silimarina in the treatment
of chronic liver diseases." Med Interne 26(4): 311-22.
-
Sarre H, Experience in the treatment of chronic hepatopathies with silymarin,
Arzneim-Forsch 1971; 21:1209-12
-
Luper S. A
review of plants used in the treatment of liver disease: Part
1. Altern Med Rev 1998. 3:410-21.
-
Bergner P. Botanical medicine: Silybum
marianum and liver therapy. Townsend Lett Doctors 1988. 61-2:348-9.
-
Hobbs C. Milk thistle: The liver herb. Loveland (CO): Interweave Press; 1994.
9. Mourelle, M., P. Muriel, et al.
(1989). "Prevention of CCL4-induced liver cirrhosis by silymarin." Fundam
Clin Pharmacol 3(3): 183-91.
10. Tkacz B, Dworniak D. Sylimarol
in the treatment of acute viral hepatitis. Pol. Wiad Lek 1983. 36:613-6.
- Saba P, Mignani E, Pagliai, et al. Efficacy of silymarin treatment of acute
virus hepatitis. Ita. Epatologia 1979. 25:277-81.
- Bode JC, Schmidt U, Durr HK. Silymarin
for the treatment of acute viral hepatitis Report of a controlled trial
author's transl. Ger. Med Klin 1977. 72:513-8.
- Magliulo E, Gagliardi B, Fiori GP. Results
of a double blind study on the effect of silymarin in the treatment of acute
viral hepatitis, carried out at two medical centres author's transl. Ger.
Med Klin 1978. 73:1060-5.
11. Giese LA. Milk thistle and the
treatment of hepatitis. Gastroenterology Nursing.
2001;24(2):95-97.
- Kiesewetter E, Leodolter I, Thaler H. Results
of two double-blind studies on the effect of silymarine in chronic hepatitis author's
transl. Ger. Leber Magen Darm 1977. 7:318-23.
12. Svagera Z, Skottova N, Vana P,
et al. Plasma lipoproteins in transport of silibinin, an antioxidant flavonolignan
from Silybum marianum. Phytotherapy
Research. 2003;17(5):524-530.
- Skottova N, Vecera R, Urbanek K, Vana P, Walterova D, Cvak L. Effects of
polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich
diets.
Pharmacology Research. 2003;47(1):17-26.
- Skottova N, Krecman V. Silymarin
as a potential hypocholesterolaemic drug. Physiology Research. 1998;47(1):1-7.
- Krecman V, Silymarin inhibits the development of diet-induced hypercholesterolemia
in rats, Planta Med 1998;64(2):138-42
- Krecman V, Skottova N, Walterova D, Ulrichova J, Simanek V. Silymarin inhibits
the development of diet-induced hypercholesterolemia in rats. Planta Medica.
1998;64(2):138-142.
- Somogyi A, Ecsedi GG, Blazovics A, Miskolczi K, Gergely P, Feher J. Short term
treatment of type II sic with silymarin. Acta Medica Hungaria. 1989;46(4):289-295.
13. Maghrani M, Zeggwagh NA, Lemhadri
A, El Amraoui M, Michel JB, Eddouks M. Study of the hypoglycaemic sic activity
of Fraxinus excelsior and Silybum marianum in an animal model of type 1 diabetes
mellitus. Journal of Ethnopharmacology. 2004;91(2-3):309-316.
- Velussi M, Cernigoi AM, Viezzoli L, et al. . Silymarin reduces hyperinsulinemia,
malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients.
Curr Ther Res Clin Exp 1993. 53:535-45.
14. Ferenci
P, Dragosics B, Dittrich H, et al. Randomized
controlled trial of silymarin treatment in patients with cirrhosis of the liver.
J Hepatol 1989. 9:105-13.
- Benda L, Dittrich H, Ferenzi P, et al. The
influence of therapy with silymarin on the survival rate of patients with liver
cirrhosis author's transl. Ger. Wien Klin Wochenschr 1980. 92:678-83.
- Salmi HA, Sarna S. Effect
of silymarin on chemical, functional, and morphological alterations of the liver. A
double-blind controlled study. Scand J Gastroenterol 1982. 17:517-21.
- Muriel P, Mourelle M. The role of membrane composition in ATPase activities
of cirrhotic rat liver: effect of silymarin. Journal of Applied Toxicology. 1990;10(4):281-284.
- Pares A, Plancs R, Torres M, et al. Effects of silymarin in alcoholic patients
with cirrhosis of the liver: results of a controlled, double-blind, randomized
and multicenter trial. J Hepatol 1998;28:615–21.
15. Trinchet
JC, Coste T, Levy VG, et al. A
randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis.
Fre. Gastroenterol Clin Biol 1989. 13:120-4.
- Pares A, Planas R, Torres M, Caballeria J, Viver JM, Acero D, et al. Effects
of silymarin in alcoholic patients with cirrhosis of the liver: results of a
controlled, double-blind, randomized and multicenter trial. Journal of Hepatology.
1998. 28(4):615-621.
- Feher J, Deak G, Muzes G, et al. Liver-protective
action of silymarin therapy in chronic alcoholic liver diseases. Hun. Orv
Hetil 1989. 130:2723-7.
- Bunout D, Hirsch S, Petermann M, et al. Controlled
study of the effect of silymarin on alcoholic liver disease. Spa. Rev Med
Chil 1992. 120:1370-5.
16. Lieber CS, Leo MA, Cao Q, Ren
C, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatic
fibrosis in baboons. Journal of Clinical Gastroenterology.
2003;37(4):336-339.
17. Chu SC, Chiou HL, Chen PN, Yang
SF, Hsieh YS. Silibinin inhibits the invasion of human lung cancer cells
via decreased productions of urokinase-plasminogen
activator and matrix metalloproteinase-2. Molecular Carcinogens. 2004;40(3):143-149.
- Valenzuela A, Garrido A. Biochemical
bases of the pharmacological action of the flavonoid silymarin and of its structural
isomer silibinin. Biol Res 1994. 27:105-12.
18. Thelen P, Wuttke W, Jarry H, Grzmil
M, Ringert RH. Inhibition of telomerase activity and secretion of prostate
specific antigen by silibinin in prostate
cancer cells. Journal of Urology. 2004;171(5):1934-1938.
- Singh RP, Agarwal R. Prostate cancer prevention by silibinin. Current Cancer
Drug Targets. 2004;4(1):1-11.
Zi X et al, Silibinin decreases prostate-specific antigen with cell growth inhibition
via G1 arrest, leading to differentiation of prostate carcinoma cells: implications
for prostate cancer intervention, Proc Natl Acad Sci U S A 1999;96(13):7490-5
- Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R. Antiproliferative
and apoptotic effects of silibinin in rat prostate cancer cells. Prostate. 2002;53(3):211-217.
- Dhanalakshmi S, Agarwal P, Glode LM, Agarwal R. Silibinin sensitizes human
prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition
and apoptotic death. International Journal of Cancer. 2003;106(5):699-705.
19. Scambia G, De Vincenzo R, Ranelletti
FO, et al. Antiproliferative effect of silybin on gynaecological sic malignancies:
synergism with cisplatin and
doxorubicin. European Journal of Cancer. 1996;32A(5):877-882.
- Tyagi AK, Agarwal C, Chan DC, Agarwal R. Synergistic anti-cancer effects
of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and
carboplatin
against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncology Reports. 2004;11(2):493-499.
- Zi X et al, Anticarcinogenic effect of a flavonoid antioxidant, silymarin,
in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase
in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent
kinases and associated cyclins, Clin Cancer Res 1998;4(4):1055-64
20. Kohno H, Tanaka T, Kawabata K,
Hirose Y, Sugie S, Tsuda H, Mori H. Silymarin, a naturally occurring polyphenolic
antioxidant
flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344
rats. International Journal of Cancer. 2002;101(5):461-468.
21. Davila,
J.C., Lenherr, A., and Acosta, D. "Protective
Effect of Flavonoids on Drug-Induced Hepatotoxicity In Vitro." Toxicology.
1989. 57(3):267-86.
- Tuchweber B, Sieck R, Trost W. Prevention
by silibinin of phalloidin induced hepatotoxicity. Toxicol Appl Pharmacol
1979;51:265–75.
- Hikino H, Kiso Y, Wagner H, Fiebig M. Antihepatotoxic
actions of flavonolignans from Silybum marianum fruits. Planta Medica 1984;50:248–50.
- Garciapina, M.P., Perez-Alvarez, V., and Mourelle, M. "Silymarin Protects
Against Paracetamol-Induced Lipid Peroxidation and Liver Damage." Journal
of Applied Toxicology. 1992. 12(6):439-42.
- Faulstich H, Jahn W, Wieland T. Silibinin inhibition of amatoxin uptake in
the perfused rat liver. Arzneim-Forsch Drug Res 1980;30:452–4.
- Palasciano G, Portinascasa P, Palmieri V, et al. The effect of silymarin on
plasma levels of malondialdehyde in patients receiving long-term treatment with
psychotropic drugs. Curr Ther Res 1994;S5:S37–45.
-
Fintelmann V, Albert A. Double blind trial of silymarin sodium in toxic
liver damage. Ger. Therapiewoche 1980. 30:5589-94.
- Magula D, Galisova Z, Iliev
N, et al. Effect of silymarine and Fumaria alkaloids in the prophylaxis of drug-induced
liver injury during antituberculotic treatment.
Slo. Stud Pneumol Phtiseol 1996. 56:206-9.
22. Studlar M. Treatment of chronic
liver disease with silymarin plus B-group vitamins. Ger. Therapiewoche
1985. 35:3375-8.
- Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the
treatment of liver disease: a systematic review and meta-analysis. American Journal
of Medicine. 2002;113(6):506-515.
- Flora K, Hahn M, Rosen H, et al. Milk
thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol
1998. 93:139-43.
- Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver
diseases. Drugs. 2001;61(14):2035-2063.
- Bode JC. . Re: Flora, et al. Silymarin
for the therapy of liver disease. Am J Gastroenterol 1999. 94:545-6.
23. Wilasrusmee C, Kittur S, Shah
G, Siddiqui J, Bruch D, Wilasrusmee S, Kittur DS. Immunostimulatory effect
of Silybum
Marianum
(milk thistle) extract. Medical
and Science Monitor. 2002;8(11):BR439-BR443.
24. Allain H, Shuck S, Lebreton S,
et al. Aminotransferase levels and silymarin in de novo tacrine-treated patients
with alzheimer's disease. Dement Geriatr
Cogn Disord 1999. 10:181-5.
25. Crocenzi FA, Sanchez Pozzi EJ,
Pellegrino JM, et al. Beneficial effects of silymarin on estrogen-induced
cholestasis in the rat: a study in vivo and in
isolated hepatocyte couplets. Hepatology. 2001;34(2):329-339.
26. Li LH, Wu LJ, Zhou B, et al. Silymarin
prevents UV irradiation-induced A375-S2 cell apoptosis. Biology and Pharmacology
Bulletin. 2004;27(7):1031-1036.
-
Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R. Silibinin prevents ultraviolet
radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine
dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis.
2004;25(8):1459-1465.
27. Berkson,
B. M. (1999). "A conservative triple antioxidant approach to the treatment
of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin,
and selenium: three case histories." Med Klin 94 Suppl 3: 84-9.
28. Buzzelli G, Moscarella S, Giusti
A, Duchini A, Marena C, Lampertico M. A
pilot study of the liver protective effect of silybin-phosphatidylcholine
complex (idb1016) in chronic active hepatitis. International Journal
of Clinical Pharmacology, Therapy, and Toxicology. 1993. 31(9):456-460.
- Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic
studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human
subjects. Eur J Drug Metab Pharmacokinet 1990. 15:333-8.
- Marcelli R, Bizzoni P, Conte D, et al. Randomized controlled study of the efficacy
and tolerability of a short course of IdB 1016 in the treatment of chronic persistent
hepatitis. Eur Bull Drug Res 1992. 1:131-5.
- Orlando R, Fragasso A, Lampertico M, et al. . Silybin kinetics in patients
with liver cirrhosis: A comparative study of silybin-phosphatidilcholine complex
and silymarin. Med Sci Res 1990. 18:861-3.
- Pifferi G, Magistretti MJ. . A new bioavailable complex of silybin: Part II.
Pharmacol Res 1993. 27:125-6.
29. Pol
S, Couzigou
P, Bourlière M, Abergel A, Combis JM, Larrey D, Tran A, Moussalli J, Poupon
R, Berthelot P, Bréchot C. A
randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone
in patients with chronic hepatitis C who were non-responders to a previous treatment.
Multicenter Study Group under the coordination of the Necker Hospital, Paris,
France. Assistance Publique/Hôpitaux de Paris, Necker, France. J Hepatol.
1999 Jul;31(1):1-7.
30. Tarantino G, Gentile A, Capone D,
Basile V, Tarantino M, Di Minno MN, Cuocolo A, Conca P. Does
protracted antiviral therapy impact on HCV-related liver cirrhosis progression
Department of Clinical and Expermtal Medicine, Federico II University Medical
School of Naples,Via S. Pansini, 5, Naples 80131, World J Gastroenterol. 2007
Sep 28;13(36):4903-8.
|
Silimarina (Silybum Marianum) numit si Armurariu, extract standardizat: Silimarina 80%, un antioxidant care neutralizeaza radicali liberi hidroxil (OH), oxigenul reactiv prin flavonoidul silibina, silibinina, si inhiba acidul arahidonic, moduleaza inflamatia articulara
